The Program — What Happens Next — The Evidence — About Dr. Hare — Why Physician-Led The Limitless Protocol Why Limitless Services — Hormone Therapy — Low Testosterone — Testosterone Pellets — Women's Hormone Therapy — Medical Weight Loss — Tirzepatide — Semaglutide — Moving Your GLP-1 Care — Peptide Therapy — Peptide Menu — Cognitive Peptides — IV Therapy & NAD+ — NAD+ IV near Chattanooga — Cost & Payment Research — Retatrutide Update — Peptide Reclassification Update — The Case for Creatine Locations Assessment Request a consultation
Clinical Update · Rewritten August 4, 2026 · Supersedes the April 28, 2026 bulletin

Tissue-Repair Peptides: Where They Actually Stand After the July Vote

An FDA advisory committee voted on July 23, 2026 to recommend adding several tissue-repair peptides to the 503A compounding list. That is a recommendation, not a rule — and the distinction is the whole story. Here is the honest version.

Author: Joshua Hare, DO Audience: Current & Prospective Patients Status: Active Clinical Bulletin

The short version

  • On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6-1 to recommend adding BPC-157, KPV, and TB-500 to the 503A bulk drug substances list — against its own FDA staff reviewers, who had recommended against all three.
  • The committee's vote is advisory and non-binding. Nothing about the legal status of these peptides changed on July 23. On October 30, HHS published an interim enforcement policy covering six peptides, including BPC-157, KPV and TB-500. HHS says it does not intend to take enforcement action against compounding that meets the policy's conditions until a final rule addresses each peptide. That policy is not binding and adds none of them to the 503A list.
  • Before any of these substances can lawfully be compounded under 503A, FDA must complete notice-and-comment rulemaking. Independent legal analysts put that at 12-24 months, with final action unlikely before late 2027.
  • Anyone marketing these peptides today as "FDA-approved," "newly legal," or "cleared" is describing something that has not happened.
  • Nothing on your Limitless protocol changed as a result of this vote.

Correcting our own earlier framing

This page previously carried the headline "Tissue-Repair Peptides Return to Legal Compounding" and told you a federal reclassification had restored physician access. We are replacing it, and we want to be explicit about why rather than quietly swapping the text.

At the July hearing, FDA's own presenter, Matthew Lash, made the point plainly: adding these substances to the 503A list would be the first time legal access was created — not restored. The earlier April framing followed the reclassification coverage of the time and got that backwards. There was no prior era of lawful 503A compounding for these specific substances to return to.

We would rather correct this in public than leave a more flattering sentence up. If you made a decision based on the earlier version of this page, please raise it at your next visit and we will walk through it with you.

"A favorable committee vote makes a peptide a candidate for legal compounding. It does not make it legal, and it does not make it clinically warranted. Those are three separate questions, and the marketing collapses all three."

What the committee actually voted

Across two days the PCAC considered seven peptides and recommended six of them for the 503A list. The recorded tallies, as we have been able to verify them:

Where these numbers come from. The meeting is the FDA's — July 23-24, 2026, Pharmacy Compounding Advisory Committee. The committee seats 14 members, and every substance was voted twice, free base and acetate. We reconciled the tallies above from contemporaneous reporting, ABC News and Healio among it. †Public accounts of the Epitalon vote differ: some report 7-4 with one abstention, others 7-5 with one abstention. The outcome — recommended — is not in dispute; the exact no-count is. We are leaving that visible rather than picking the tidier number, and we will reconcile it against FDA's official minutes and transcript when they post.

Two things worth noticing. First, these were close votes on a divided panel, not a consensus endorsement — several members who voted yes said openly that they were reasoning from the reality of gray-market access rather than from the statutory criteria. Second, FDA reviewed each substance for specific uses, listed above. A favorable vote on BPC-157 for ulcerative colitis is not a favorable vote on BPC-157 for tendon repair, and any clinic implying otherwise is overreading the record.

What happens next, and how long

The committee advises; FDA decides. The agency has said it will not issue a final determination until it has considered the committee process and completed its own reviews, and that any addition to the 503A list proceeds through formal notice-and-comment rulemaking — a draft rule, a public comment period, and a final rule. Two law-firm analyses of the vote read it the same way: Mintz, in FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do, and Holland & Knight's August note, which frames the vote as "a step toward" eligibility for lawful compounding rather than the thing itself.

Prior 503A bulks-list cycles have run roughly 8 to 24 months end to end. Kelley Drye & Warren, writing after the July vote, said the process "may take over a year." Our working expectation is 12-24 months, with final action unlikely before late 2027. We will revise that publicly if the agency moves faster.

A second PCAC meeting is planned before the end of February 2027 to review five more peptides: GHK-Cu, Melanotan II, LL-37, dihexa acetate, and PEG-MGF (McDermott Will & Schulte; Mintz, above).

Why the "green light" reading is a real risk

Since the vote, several clinics and telehealth companies have begun advertising these peptides as though the question is settled. Kelley Drye has also been direct about the exposure: treating the committee vote as a green light carries enforcement risk until FDA formally lists a substance. FDA announced 30 warning letters to telehealth companies in March 2026, all 30 bearing the same date, and its warning-letter database lists more than 80 sent to such companies over the past year. Those letters were overwhelmingly about advertising claims, not about the medicine itself.

There is a second, sharper problem. The PCAC record now contains FDA's documented assessment that the human evidence for these substances is thin. That record makes phrases like "clinically proven," "clinically tested," or "incredibly safe" harder to defend, not easier — a claim of proof is now contradicted by a federal advisory record. That is FTC Act territory as well as FDA's.

What this means for your protocol

Three things to know

  • Nothing changed on your protocol. We did not add anything to the menu on the strength of a committee vote, and we will not until the substance is lawfully compoundable and the clinical case stands on its own.
  • Sourcing remains non-negotiable. We work only with licensed 503A pharmacies holding current state board accreditation, with per-lot certificates of analysis and third-party USP <797> sterility documentation. We do not use "research use only" material.
  • Legality and clinical warrant are separate gates. A peptide has to clear both before it enters the Limitless protocol library. The July vote moves one of those gates, slowly, and does not touch the other.

What we are not doing

We are not chasing every peptide that moves through a committee. The Limitless protocol library stays disciplined: peptides earn inclusion on mechanism, evidence, and safety — not regulatory novelty. We are also not going to tell you the evidence is stronger than it is. For most of these substances the preclinical literature is genuinely interesting and the completed human trials are genuinely missing. Both of those things are true at once, and the physician's job is to live in that gap honestly.

Questions you may have

Does my protocol change because of the vote? No. If your protocol were going to change, it would change because of your labs and your response to therapy, not because of a 8-6-1 committee tally.

I saw a headline saying these peptides were "added to the FDA list." Was that wrong? Yes — and it has appeared in otherwise reputable legal trade press more than once. They were recommended for addition by an advisory committee. Nothing has been added.

Is a tissue-repair peptide right for me? That is a clinical question, answered from your history, your labs, and your goals — physician-determined, and prescribed only where lawful and indicated as part of a full protocol review.

What about DSIP, since the panel said no? DSIP was the one substance the committee declined. We do not prescribe it, and we would treat any clinic advertising it in a named sleep blend as a signal about how that clinic reads regulatory information generally.

Will insurance cover any of this? No. Compounded peptides are not reimbursable under any commercial or government plan.

Sources

  1. FDA — July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (docket FDA-2025-N-6895). fda.gov
  2. ABC News, July 2026 — "FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list." abcnews.com
  3. Healio, July 24, 2026 — "FDA committee recommends looser restrictions for several peptides." healio.com
  4. Mintz, July 29, 2026 — "FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do." mintz.com
  5. Holland & Knight, August 2026 — "FDA Advisory Committee Endorses Compounding of Certain Peptides." hklaw.com
  6. McDermott Will & Schulte, July 27, 2026 — "PCAC backs majority of peptides in two-day public meeting." mcdermottlaw.com
  7. Kelley Drye & Warren, July 30, 2026 — "FDA Advisory Committee Recommends Several Peptides for Compounding for Various Uses Despite Staff Opposition: What Stakeholders Need to Know." kelleydrye.com
  8. FDA, March 3, 2026 — "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s." fda.gov
  9. FDA — "FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs." The page points to the agency's warning-letter database. A search of that database for "telehealth" returns 58 letters dated September 9, 2025; 30 dated February 20, 2026; and 25 dated June 8, 2026. fda.gov

The fuller source list — the national reporting, the trade press, and the other law-firm analyses — is on the post-vote read.

Joshua Hare, DO
Founder & Medical Director · Limitless Performance Medicine
Read the evidence

The full post-vote read — recorded tallies for all seven substances, what the press coverage got right and blurred, and what a recommendation does and does not do. The vote is in — six of seven recommended →

Live tracker: PCAC Watch 2026 · Evidence dossier: BPC-157 at the FDA · Companion: Peptides — what's real, what's risky, what we prescribe